$14.910
+1.806 (+12.11%)Zum Schluss
Kursprognosen
In der App öffnen, um Prognosen mit längerem Horizont freizuschalten.
Soll ich ADARx Pharmaceuticals, Inc.-Aktien kaufen?
ADARx Pharmaceuticals is not a good buy right now due to its significant losses and declining stock performance. The current price is $13.15, which is 43.4% below its 52-week high of $23.21. Additionally, the company reported a net income loss of $25,759,000 in Q2 2026, indicating ongoing financial struggles. The main risk is its high price-to-sales ratio of 240.20, suggesting overvaluation relative to its revenue.
ADRX schloss am Thursday bei $14.91, nachdem der Kurs +12.11% gestiegen ist
ADARx Pharmaceuticals, Inc. (ADRX) last closed at $14.9099998, gaining +12.11%. These facts feed the 1-day and 1-week ADRX price prediction above.
Prognose-Treiber
Die Prognose-Treiber von ADARx Pharmaceuticals, Inc. (ADRX) kombinieren ähnliche Chartmuster, Saisonalität und gleitende Durchschnitte.
Seasonality
Bearish
SMA 20
Bearish
SMA 200
Bearish
Saisonalitätsanalyse für ADRX
Ähnliche Artikel
- International Stocks vs US Stocks in 2026: How the Strong Dollar and Valuations Change the CaseInternational stocks vs US stocks in 2026: how the strong dollar, valuation gaps, Fed hikes and concentration risk shape a smarter global allocation plan now.
- Defensive Stocks in 2026: Is the Rush Into Staples and Healthcare Already Overcrowded?Investors are piling into defensive stocks as tech slides. See why staples and healthcare surged, why valuations look stretched, and how to avoid overpaying.
- Defense Stocks in 2026: How Midterms, the Iran War and a Stalled Budget Shape the OutlookDefense stocks fell after the 2026 midterms. Learn how the Iran war, the $1.5T budget request and the December 11 funding deadline shape the sector outlook.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.